Real-World Evidence and Multidrug Resistant Infections: How Can We Leverage RWE to Improve Patient Outcome with the Novel Beta-Lactam and Beta-Lactam/Beta-Lactamase Inhibitor Combinations - PubMed
4 hours ago
- #Beta-Lactamase Inhibitors
- #Real-World Evidence
- #Multidrug-Resistant Infections
- The article discusses leveraging Real-World Evidence (RWE) to improve patient outcomes with novel beta-lactam and beta-lactam/beta-lactamase inhibitor combinations (BL/BLIc) for multidrug-resistant Gram-negative infections.
- It highlights the importance of RWE in addressing limitations of pivotal trials and optimizing therapy for infections caused by ESBL-producing Enterobacterales, CPE, MBL-producing Pseudomonas aeruginosa, and CRAB.
- Four therapeutic algorithms are proposed based on pathogen susceptibility, resistance genotype, and PK/PD features of selected agents.
- Cefepime-enmetazobactam is suggested as a carbapenem-sparing strategy for ESBL-producing Enterobacterales and an alternative for OXA-48-producing infections.
- Cefepime-taniborbactam, cefepime-zidebactam, and aztreonam-avibactam are identified as potential solutions for MBL-producing Enterobacterales and Pseudomonas aeruginosa infections.
- Sulbactam-durlobactam is recognized by international guidelines for CRAB infections.
- The article emphasizes the need for well-designed RWE studies and PK/PD models to refine therapeutic algorithms and improve clinical practice.